IMNN confirms Phase III trial progress, targeting final enrollment milestone for its OVATION 3 study next year.
Imunon announced plans to complete last patient enrollment for its pivotal Phase III OVATION 3 study in Q1 2029. The company cited strong momentum following the release of final clinical data from its Phase II OVATION 2 trial in Q1 2026.
Management stated the OVATION 3 trial is advancing as planned, with no delays reported. The company also outlined preferred-share financing options to support ongoing operations and trial execution.
Shares of IMNN showed limited immediate reaction to the update during the earnings call.